We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Overtesting for Diabetes Tends to Reap Negative “Rewards”

By LabMedica International staff writers
Posted on 23 Dec 2015
Researchers report a US national trend toward overtesting of glycated hemoglobin (HbA1c) levels in adult patients with Type 2 diabetes, leading to unnecessary cost, time, and other burdens for patients and providers, as well as potential patient health complications due to overtreatment with hypoglycemic drugs.

A new study led by Mayo Clinic (Rochester, MN, USA) researchers has shown that patients with Type 2 diabetes are often tested much more frequently than clinically indicated. More...
Type 2 diabetes monitoring and treatment protocols are not well defined by professional societies and regulatory bodies. While lower thresholds of testing frequencies are often discussed, the upper boundaries are rarely mentioned. Yet, most agree that checking 1–2 times/year should suffice for adult patients who are not using insulin, have stable glycemic control within the recommended targets, and have no history of severe hypoglycemia or hyperglycemia. Yet, in practice, there is a much higher prevalence of excessive testing.

Upon examining a national cohort of 31,545 non-pregnant adults with controlled non-insulin-treated Type 2 diabetes, the investigators said the study provides definitive evidence of such excess testing. The patient cohort examined was derived from the OptumLabs Data Warehouse (OLDW) using de-identified administrative, pharmacy, and laboratory data from 2001 to 2011. Approximately 55% achieved and maintained the recommended less than 7% HbA1c level and were tested 3–4 times/year; 6% were tested 5 or more times.

“Our findings are concerning, especially as we focus more on improving the value of care we deliver to our patients—not only ensuring maximal benefit, but also being mindful of waste, patient burden, and healthcare costs,” said study lead investigator Rozalina McCoy, MD, Mayo Clinic, “As providers, we must be ever vigilant.”

“Potential reasons for more frequent testing include clinical uncertainty; misunderstanding of the nature of the test—that is, not realizing that HbA1c represents a 3-month average of glycemic control; or a desire for diagnostic and management thoroughness,” said Dr. McCoy, “Other times, it may be the result of fragmentation of care (more than one unconnected provider); the need to fulfill regulatory demands, such as public reporting of performance metrics; or internal tracking of performance. “Because our culture often thinks that more is better” patients and providers may favor additional testing due to a desire for comprehensive care, she added.

The researchers also found that excessive testing increased the odds of overtreatment with one or more drugs, despite normal HbA1c levels, and that rates of overtesting were lower among patients receiving bundled testing (i.e., cholesterol, creatinine, and HbA1c tests in the same day).

“We hope that these findings will help inform decision-making,” said Dr. McCoy.

The study was published December 8, 2015, in the British Journal of Medicine.

Related Links:

Mayo Clinic
Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
OptumLabs 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.